# S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

> **NCT05101070** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shionogi** · enrollment: 282 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** S-531011
- **DRUG:** Pembrolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05101070
- **Lead sponsor:** Shionogi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-30
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 282 (ESTIMATED)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05101070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05101070, "S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05101070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*